These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Assessment of cerebral benzodiazepine receptor distribution in epilepsy by 123I-iomazenil-SPECT]. Uchiyama M, Sue H, Fukumitsu N, Mori Y, Kawakami K. Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Jan; 57(1):47-51. PubMed ID: 9038063 [Abstract] [Full Text] [Related]
6. [Assessment of cerebral benzodiazepine receptor distribution in anxiety disorders by 123I-iomazenil-SPECT: comparison to cerebral perfusion scintigraphy by 123I-IMP]. Uchiyama M, Sue H, Fukumitsu N, Mori Y, Kawakami K. Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Jan; 57(1):41-6. PubMed ID: 9038062 [Abstract] [Full Text] [Related]
7. A method for the quantification of benzodiazepine receptors by using 123I-iomazenil and SPECT with one scan and one blood sampling. Ito H, Kawashima R, Koyama M, Goto R, Sato K, Ono S, Fukuda H. Ann Nucl Med; 1997 May; 11(2):101-8. PubMed ID: 9212889 [Abstract] [Full Text] [Related]
8. Assessment of benzodiazepine receptors using iodine-123-labeled iomazenil single-photon emission computed tomography in patients with ischemic cerebrovascular disease. A comparison with PET study. Dong Y, Fukuyama H, Nabatame H, Yamauchi H, Shibasaki H, Yonekura Y. Stroke; 1997 Sep; 28(9):1776-82. PubMed ID: 9303025 [Abstract] [Full Text] [Related]
9. [Compartment analysis of 123I-iomazenil brain SPECT in patients with moyamoya disease]. Kaneta T, Yamazaki T, Maruoka S, Abe Y, Takahashi S, Yamada S. Kaku Igaku; 1999 Dec; 36(9):1007-12. PubMed ID: 10659585 [Abstract] [Full Text] [Related]
12. [Phase 2 clinical study of 123I-iomazenil in various cerebral diseases: part 1--examination of injection dose and clinical indications]. Torizuka K, Uemura K, Tohru M, Yonekura Y, Nakagawara J, Fukuyama H, Matsuda K, Morimoto K. Kaku Igaku; 1996 Feb; 33(2):179-90. PubMed ID: 8721107 [Abstract] [Full Text] [Related]
13. Iodine-123-iomazenil and iodine-123-iodoamphetamine SPECT in major cerebral artery occlusive disease. Moriwaki H, Matsumoto M, Hashikawa K, Oku N, Ishida M, Seike Y, Fukuchi K, Hori M, Nishimura T. J Nucl Med; 1998 Aug; 39(8):1348-53. PubMed ID: 9708504 [Abstract] [Full Text] [Related]
14. [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 4)--Report on clinical usefulness in diagnosis of cerebrovascular diseases]. Torizuka K, Uemura K, Toru M, Shinohara Y, Nishimura T, Yonekura Y, Nakagawara J, Matsuda H, Sakai F, Matsuda K, Fukuyama H, Morimoto K. Kaku Igaku; 1996 Mar; 33(3):329-44. PubMed ID: 8622266 [Abstract] [Full Text] [Related]
16. Asymmetries of benzodiazepine receptor binding potential in the inferior medial temporal lobe and cerebellum detected with 123I-iomazenil SPECT in comparison with 99mTc-HMPAO SPECT in patients with partial epilepsy. Kuji I, Sumiya H, Tsuji S, Ichikawa A, Tonami N. Ann Nucl Med; 1998 Aug; 12(4):185-90. PubMed ID: 9795703 [Abstract] [Full Text] [Related]
18. Pharmacokinetic analysis of benzodiazepine receptor binding of [123I]iomazenil in human brain. Ito K, Momose T, Kotaki H, Kojima Y, Yamamoto K, Katashima M, Sawada Y, Sasaki Y, Iga T. Pharm Res; 1997 Aug; 14(8):999-1003. PubMed ID: 9279879 [Abstract] [Full Text] [Related]